Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
AZN

Price
209.48
Stock movement down
-3.96 (-1.90%)
Company name
AstraZeneca PLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
634.56B
Ent value
694.21B
Price/Sales
10.80
Price/Book
13.02
Div yield
0.50%
Div growth
2.25%
Growth years
2
FCF payout
47.03%
Trailing P/E
62.06
Forward P/E
40.23
PEG
3.27
EPS growth
40.08%
1 year return (CAGR)
177.28%
3 year return (CAGR)
42.76%
5 year return (CAGR)
31.68%
10 year return (CAGR)
21.52%
Last updated: 2026-02-20

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.03
Dividend yield0.50%
Payout frequency-
Maximum yield3.85%
Average yield2.13%
Minimum yield0.49%
Discount to avg yield-322.90%
Upside potential-76.35%
Yield as % of max yield13.06%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield0.50%
Current yield distribution99.52%
Yield at 100% (Min)0.49%
Yield at 90%1.26%
Yield at 80%1.35%
Yield at 50% (Median)1.70%
Yield at 20%3.00%
Yield at 10%3.26%
Yield at 0% (Max)3.85%

Dividend per share

Loading...
Dividend per share data
Years of growth2 years
CCC status-
Dividend per share1.03
Payout frequency-
Ex-div date19 Feb 2026
EPS (TTM)6.55
EPS (1y forward)5.09
EPS growth (5y)40.08%
EPS growth (5y forward)19.00%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
AZNS&P500
DGR MR-50.95%-13.74%
DGR TTM5.39%6.60%
DGR 3 years2.58%7.31%
DGR 5 years2.25%4.69%
DGR 10 years1.12%6.30%
DGR 15 years1.76%8.16%
Time since last change announced210 days
EPS growth (5y)40.08%
EPS growth (5y forward)19.00%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM48.71%47.03%
Average--
Forward20.24%-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E62.06
Price to OCF43.28
Price to FCF59.93
Price to EBITDA31.86
EV to EBITDA34.85

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales10.80
Price to Book13.02
EV to Sales11.82

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count3.10B
EPS (TTM)6.55
FCF per share (TTM)6.78

Income statement

Loading...
Income statement data
Revenue (TTM)58.74B
Gross profit (TTM)48.11B
Operating income (TTM)13.74B
Net income (TTM)10.22B
EPS (TTM)6.55
EPS (1y forward)5.09

Margins

Loading...
Margins data
Gross margin (TTM)81.90%
Operating margin (TTM)23.40%
Profit margin (TTM)17.41%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash5.71B
Net receivables15.18B
Total current assets28.72B
Goodwill21.24B
Intangible assets37.85B
Property, plant and equipment14.70B
Total assets114.07B
Accounts payable25.28B
Short/Current long term debt29.70B
Total current liabilities30.62B
Total liabilities65.36B
Shareholder's equity48.72B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)14.66B
Capital expenditures (TTM)4.07B
Free cash flow (TTM)10.59B
Dividends paid (TTM)4.98B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity20.99%
Return on Assets8.96%
Return on Invested Capital13.28%
Cash Return on Invested Capital13.75%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open206.60
Daily high207.69
Daily low204.05
Daily Volume1.53M
All-time high209.48
1y analyst estimate113.50
Beta0.19
EPS (TTM)6.55
Dividend per share1.03
Ex-div date19 Feb 2026
Next earnings date-

Downside potential

Loading...
Downside potential data
AZNS&P500
Current price drop from All-time high-2.17%-0.86%
Highest price drop-54.44%-56.47%
Date of highest drop9 Mar 20099 Mar 2009
Avg drop from high-15.54%-10.84%
Avg time to new high28 days12 days
Max time to new high1837 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AZN (AstraZeneca PLC) company logo
Marketcap
634.56B
Marketcap category
Large-cap
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the Uni
Employees
94300
SEC filings
CEO
Pascal Soriot
Country
USA
City
Cambridge
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...